ロード中...
The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas
Our group previously demonstrated that sarcoma cell lines were insensitive to epidermal growth factor receptor (EGFR) inhibitor gefitinib monotherapy. PENAO, an anti-tumour metabolic compound created in our laboratory, is currently in clinical trials. Considering the positive regulation of tumour en...
保存先:
| 出版年: | Oncotarget |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Impact Journals LLC
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6967775/ https://ncbi.nlm.nih.gov/pubmed/32002123 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27416 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|